Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by major fibro-fatty replacement of the right ventricle (RV). We hypothesized that changes in peroxisome proliferatoractivated receptor (PPAR) signalling contributed to myocardium fatty accumulation and contractile dysfunction in ARVC. Methods and results Real-time quantitative reverse transcriptase-polymerase chain reaction and western blotting were used to assess cardiac expression of PPARa and g and two of their downstream target genes-medium-chain acyl-CoA dehydrogenase (MCAD) and phosphoenolpyruvate carboxykinase (PEPCK)-in both RV and left ventricle (LV) from five controls and five ARVC patients. In vitro motility assays were used to analyse functional properties of myosin. In the RV, sliding velocity was nearly two-fold lower in ARVC than in controls, whereas a 10% reduction in velocity values was noted between ARVC and non-failing myocardium in the LV. In controls, PPARa and MCAD mRNA and protein levels were higher in the RV compared with the LV. In ARVC, the expression of PPARa and MCAD mRNA and/or proteins was decreased in both RV and LV. RV from ARVC was also characterized by a dramatic activation of the PPARg pathway, as attested by the increase in PPARg mRNA and protein (500 and 270%, respectively, each P , 0.001) and by the induction of PEPCK gene. In contrast, the LV of ARVC heart exhibited no changes in the expression of the PPARg regulatory pathway compared with control. Conclusion ARVC is associated with major disturbances in the PPARa and PPARg signalling pathway in the RV that may contribute to intracellular lipid overload and severe myosin dysfunction.
Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a form of cardiomyopathy primarily affecting the right ventricle (RV) and characterized by major fibro-fatty replacement of the myocardium. 1 ARVC is a clinically heterogeneous disease, which typically manifests as lifethreatening ventricular arrhythmias in apparently healthy young adults. Progressive left ventricular (LV) dysfunction has been found to occur in at least 20% of cases, 2 and in the severe forms, the disease may require heart transplantation. 1 The pathogenesis of the disease is still largely unknown. Genetic studies have located 11 different loci associated with ARVC and mutations in eight genes have been identified, pointing out a high genetic heterogeneity. 3 Understanding of ARVC pathogenesis mostly relies on patient heart examination. 4 Histological findings suggest that the lipomatous replacement occurs in the context of cardiac myocyte loss due to metabolic, ultrastructural, inflammatory, or apoptotic injuries. 5 Progressive lipid accumulation within the cardiomyocyte has been observed in ARVC 6 and is thought to contribute to the pathogenesis. In fact, myocardial lipid accumulation is probably involved in contractile dysfunction and in the generation of cardiac arrhythmias in several other pathological states. 7, 8 The molecular events underlying myocardium fatty infiltration are presently unknown. In the last 10 years, the peroxisome proliferator-activated receptor (PPAR) family of ligand-activated transcription factors has been shown to play a paramount role in regulating cellular lipid metabolism. 9 It is now established that the alpha isoform of PPAR regulates cardiac fatty acid utilization pathways, through transcriptional control of numerous genes involved in fatty acid uptake and oxidation. 10, 11 Knockout mice studies have demonstrated that PPARa acts as a 'lipostat' to regulate cardiac lipid homeostasis, 12 and impairments in heart PPARa gene regulatory pathways have been characterized in various mouse models. [13] [14] [15] However, few data are available on PPARa expression and activity in the diseased human heart. 16, 17 PPARg, another member of the PPAR family, is highly expressed in tissues involved in lipogenesis, in particular in the white adipose tissue in which it promotes cellular differentiation and fat storage. 9, 18 Consistent with the limited lipogenesis of cardiomyocytes, the mouse heart exhibits low levels of PPARg. In the human heart, PPARg gene expression has been detected in the coronary arteries, aorta, LV, and atrium, but there is little information on the expression and function of PPARg under pathological conditions. [19] [20] [21] [22] In the present study, we obtained cardiac samples from five cases of ARVC with severe RV and LV dysfunction, and we investigated histological, functional, and molecular features in both ventricles of ARVC heart. Our main objectives were to characterize possible alterations in cardiac myosin functional properties, and associated changes in the expression of PPARs and of PPAR target genes, in RV and LV of diseased heart.
Methods
The investigation conforms with principles outlined in the Declaration of Helsinki. The informed consent was obtained from all patients or relatives participating in the study according to the protocol approved by the Local Ethics Committee (Consultative Committee for the Protection of Human Subjects in Biomedical Research at the Pitié-Salpêtrière Hospital, Paris, France).
Clinical characterization of ARVC patients and cardiac specimens
The ARVC study population comprised five patients (four males/one female) aged from 13 to 74 years ( Table 1) . Patients met the Task Force definition of ARVC ( Table 1) . 23 In four patients, ARVC cardiac specimens from left and right ventricular free wall were obtained at the time of heart transplantation. For the fifth patient, ARVC cardiac specimens from right ventricular free wall were obtained during cardiac surgery. Analysed ARVC samples typically presented RV myocardium with fatty infiltration ( Figure 1A) . Non-failing RV and LV specimens, obtained from five cardiac donors (three males/two females, mean age + SD 14 + 7 years) without previous medical history or any abnormalities in ECG and echocardiography (LV dimensions/contractility within normal ranges), were used as controls ( Table 2) . They were rejected for transplantation for other reasons than depressed cardiac function. All specimens were shock-frozen in liquid nitrogen immediately after heart removal and cryo-conserved at 2808C for further analysis.
Morphometry and immunolabelling
For histology, 5 mm paraffin sections of cardiac tissue were stained with haematoxylin and eosin and Masson's trichrome. Frozen sections were stained with oil red O and counterstained with haematoxylin to detect neutral lipids. Anti-a actinin (Sigma, France), MLC1 antibodies (Biocytex, France), FITC-labelled anti-mouse IgG antibodies (Amersham, France), and 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories, CA, USA) were used for immunolabelling. Intensity of myosin labelling was quantified using Metamorph. For each section, three to four fields were randomly selected. Segments representing muscle fibres were identified and a computer was programmed to calculate the average intensity of the stained regions. The results are given in arbitrary units. A minimum of five fields/heart were measured.
Preparation of human cardiac myosin and rabbit actin filaments
Myosin was isolated from the ventricular muscular specimens as described previously 24 and used within 48 h of the experiments. Actin was prepared from rabbit back muscle and fluorescently labelled with tetramethylrhodamine-phalloidin (Molecular Probes).
In vitro motility assays
In vitro motility assays were performed at 308C as described previously. 24, 25 Videotape recordings were made when .85% of all actin filaments over myosins were moving continuously within a visual field and analysed using RETRAC program (N. Carter, The Marie Curie Research Institute, UK).
ATPase assays
Actin-activated myosin ATPase activity was determined at 218C. 26 The maximal actomyosin ATPase activity (K cat , in s 21 ) and the association constant of myosin for actin (K m ) were determined from a double-reciprocal Lineweaver-Burk plot of the ATPase rate vs. actin concentration.
Real-time quantitative polymerase chain reaction
Total RNAs were isolated from quick-frozen heart samples using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples treated with RNase-free DNase I (Ambion, UK) were reverse-transcribed into cDNA using the kit from Invitrogen and quantified using the SYBR Green I kit from Roche Diagnostics (Mannheim, Germany). Real-time quantitative polymerase chain reaction (RTQ-PCR) was performed using a Light Cycler instrument (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. RTQ-PCR primers (Table 3) were designed using the sequences available in GenBank and spanned an intron/exon boundary. The amounts of the various mRNAs were normalized to the amount of 18S ribosomal RNA measured by RTQ-PCR in each sample. The results of RTQ-PCR are given in arbitrary units.
Western blot analysis
Protein extracts of RV and LV samples from control or ARVC patients (fat free) were prepared in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, 10 mg/mL leupeptin, 10 mg/mL aprotinin, and 1 mM phenylmethylsulfonyl fluoride) according to standard methods. Protein concentration was determined using the Bradford method. 
Statistical analysis
Data are expressed as mean + SD. In each control or ARVC patient, the mean velocity was calculated from 50 actin filaments. Differences between groups were analysed by one-way ANOVA and the Fisher test. In addition, the Kolmogorov-Smirnov test was used to analyse potential difference between velocity distribution in control and ARVC myosins. A value of P , 0.05 was considered significant.
Results

Morphological analyses
Representative control and ARVC myocardium specimens are illustrated in Figure 1 . In ARVC, the right myocardium showed extensive fatty replacement of the myocardium, whereas LV involvement was characterized by a diffuse increase in interstitial fibrosis ( Figure 1A and B) . Surviving RV myocardium exhibited severe fatty infiltration of myocardial cells that was not observed in the RV from control subjects ( Figure 1B) . In the LV, there was a trend for increased intramyocardial lipid deposition in ARVC patients, whereas sections from controls were negative for neutral lipid accumulation ( Figure 1C ). 
Myosin properties and distribution in ARVC and control hearts
Mean velocities of actin filament sliding over myosins from control and ARVC myocardium are presented in Figure 2A .
Sliding velocity was nearly two-fold slower in ARVC than in control RV (P , 0.0001). In the LV of diseased heart, a decrease of myosin velocity values was also observed, but it was more limited in amplitude (around 210%, P , 0.001) than in the RV. The effects of actin on the myosin ATPase activity for human ventricular myosin isolated from control and dysplastic myocardium are presented in Table 4 . In both ventricles, the V max obtained from ARVC was significantly lower than in controls. K m values did not differ between groups. Because abnormalities in MLC1 may reduce in vitro myosin sliding velocity, 27 the distribution of MLC1 was assessed in both ARVC and control ventricles by using anti-MLC1 antibodies. As shown in Figure 2B , no changes were found in labelling intensity or distribution between ARVC and control cardiomyocytes.
Expression of PPARs and PPAR target genes in control heart ventricles
The expression levels of PPARa and PPARg genes in the RV and LV of control hearts are shown in Figures 3 and 4 . PPARa mRNA and protein levels appeared higher in the RV compared with the LV. Consistent with this, gene expression and protein levels of MCAD, a typical PPARa target gene, were also found higher in RV compared with LV. Both ventricles exhibited comparable levels of PPARg transcripts and protein. Transcript levels of PEPCK, a known PPARg target gene, were quite low in both ventricles of control heart, and similar PEPCK protein levels were found in the RV and LV of control hearts.
Changes in the expression patterns of PPARs and PPAR target genes in cardiac ventricles from ARVC patients
PPARa gene expression level was markedly reduced (250%; P , 0.01) in the patient RV compared with controls, whereas the decrease observed in the LV was not significant (Figure 3) . Marked decreases in PPARa protein levels were observed in patient RV (250%; P , 0.05) and LV (260%; P , 0.05), compared with control ( Figure 4) . Similarly, significant decreases in MCAD mRNA ( Figure 3 ) and protein levels ( Figure 4) were observed in both patient ventricles (RV 240%, P , 0.05; LV 260%, P , 0.05). Altogether, these PPARa  TGAAGGCTGCAAGGGCTTCTT  CAGATCTTGGCATTCGTCCAAA  PPARg  TTCAAGAGTACCAAAGTGCAATC  AGGATGCAAGGGTTTCTTCCG  PEPCK  GCTCTGAGGAGGAGAATGG  TGCTCTTGGGTGACGATAAC  MCAD  AACTGGTGAATATCCAGTCCCC  GGGTTCAGACTGCTATTGAAGG  18S CCGCTAGAGGTGAAATTCTTGG GCATCGTTTATGGTCGGAACTA data reflected a global downregulation of PPARa regulation in patient LV and RV. The pattern of changes observed for PPARg in ARVC heart markedly differed from that found for PPARa. Indeed, dramatic increases in PPARg mRNA (500%; P , 0.001) ( Figure 3 ) and protein level (270%; P , 0.01) ( Figure 4) were noted in patient RV, whereas no significant changes occurred in the LV. Upregulation of PPARg in the RV went together with a robust induction of its target gene, as indicated by the increase in PEPCK gene expression (22.5-fold) ( Figure 3 ) and protein level (2.8-fold) (Figure 4) . In contrast, PEPCK mRNA and protein levels remained unchanged in patient LV, compared with control.
Discussion
Human ARVC is characterized by a progressive, fatty replacement occurring predominantly in the RV, possibly leading to severe cardiac failure. Although disease mechanisms remain poorly understood, the pathogenesis of ARVC is obviously reminiscent of a major disturbance in cardiac muscle lipid homeostasis. In the present study, we analysed a small series of ARVC heart biopsies to characterize structural and functional alterations, and to study possible changes in PPAR regulatory pathways, in patient RV and LV.
Our results point out that ARVC is associated with pronounced alterations in myosin function, revealed in particular by markedly reduced sliding velocity values in the dysplastic RV. Furthermore, a moderate decrease in sliding velocity values was noted in patient LV, in which histological observation revealed more fibrosis and larger muscular areas compared with the RV, in keeping with previous reports. 4 Histological observation also showed fatty infiltration occurred predominantly in the RV, as reported previously. Thus, although there are a plethora of potential mechanisms of myocardial dysfunction apart from actomyosin dysfunction, myosin dysfunction was therefore clearly associated with abnormal myocardial lipid accumulation in the RV. It was shown in different animal models that alterations in lipid homeostasis can severely compromise contractile function of myocardial cells. 14, 28, 29 Proposed mechanisms include direct toxic effects of lipid droplets or fatty acid species on myofibrillar function, or increased substrates for ceramide production possibly leading to the generation of reactive oxygen species and activation of the apoptotic pathways. 7, 28, 30, 31 Interestingly, it has been suggested that apoptosis might be involved in ARVC pathogenesis in children 32 and adults. 33 Activation of caspase-3, a key effector enzyme of myocardial apoptosis, could mediate the cleavage of several muscle cytoskeletal proteins, including the essential myosin light chain, MLC1. 31 It was thus tempting to speculate that the reduced actin velocity observed in the right dysplastic ventricle was related to proteolytic cleavage of MLC1. However, we did not find evidence for morphological disruption of the organized MLC1 in ARVC. It remains possible that cardiac lipid accumulation induces other subtle structural changes in the myosin molecular motor that impaired its mechanical properties.
The PPAR signalling pathway clearly plays a pivotal role in the control of cardiac lipid metabolism in rodents, 13 but there is little information on this regulatory pathway in the human heart. Our study documents the compared expression levels of PPARa and PPARg in the RV and LV of the human heart and their possible changes under pathological conditions. In keeping with the high b-oxidation capacity, we found high expression levels of PPARa and of MCAD in both LV and RV of control heart. In contrast, PPARg was expressed to low levels in both heart ventricles, consistent with data obtained in mice, 14, 34 and PEPCK mRNA levels were also faint in both ventricles of control heart. Expression pattern of PPARs and their target genes was markedly modified in ARVC heart, compared with control. Interestingly, opposite changes in PPARa and PPARgdependent pathways were observed in the diseased heart. Indeed, mRNA and protein levels of PPARa and MCAD were downregulated in the RV and LV, suggesting a global impairment of fatty acid b-oxidation in both ventricles. In contrast, a dramatic increase in PPARg and a strong induction of its target gene PEPCK were observed in the RV. Recent studies in transgenic mice showed that forced expression of PPARg in heart resulted in severe cardiac dysfunction, possibly leading to premature death. 19 Metabolic alterations in these animals included abnormal heart lipid accumulation, which was ascribed to constitutive stimulation of fatty acid uptake. Accordingly, cardiac lipid overload in PPARg transgenic mice likely reflected imbalance between Figure 3 mRNA levels of PPARa, PPARg, and their respective target genes in the right and left human heart ventricles in patients or control individuals. Results were expressed as relative quantification, taking the value measured in the control RV as reference. Values are means + SD of five different control individuals or five ARVC patients. For each individual, the values were obtained from three independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001 compared with the respective control group. fatty acid supply and mitochondrial fatty acid utilization, a situation known to promote lipotoxicity. 19 Results obtained in our study indicate that upregulation of PPARg and PEPCK in the patient RV occurred in the context of a decreased fatty acid b-oxidation, which could clearly favour the development of lipid accumulation. Indeed, in the white adipose tissue, upregulation of PEPCK increases the storage of fatty acids in the form of triglycerides, by promoting de novo synthesis of glycerol. 35 This mechanism is strictly controlled by PPARg, 36 whose activation depends on the concentration of activating ligands, in particular fatty acids. In ARVC heart, the decreases in PPARa and b-oxidation might favour accumulation of fatty acids, which could then act as activators of PPARg. The resulting induction of PPARg target genes could, in turn, amplify the imbalance between fatty acid supply and their b-oxidation, creating conditions for overt lipid accumulation. Interestingly, mice knockout models of desmoplakin, one of the candidate genes for ARVC in human, exhibit a marked increase in cardiac expression of PPARg and some of its target genes. 37 Our results in ARVC heart also point out that the induction of PPARg regulatory pathway was restricted to Figure 4 Protein levels in the right and left human heart ventricles in patients or control individuals. Representative western blots of two controls and two patients are shown. Results were expressed as relative quantification, taking the value measured in the control RV as reference. The PPARa, PPARg, MCAD, and PEPCK protein amounts were corrected by the amount of calsequestrin protein. Histogram values are means + SD of five different control individuals or five ARVC patients. Western blot experiments were performed at least twice. *P , 0.05, **P , 0.01, ***P , 0.001 compared with the respective control group. the RV, in which adipose phenotype was predominant. This could suggest that distinct pathogenic mechanisms operate in both ventricles, involving PPARg in the RV, but not in the LV. Alternatively, alterations in the LV, which appeared less pronounced than in the RV, might reflect milder stages of myocardium fibro-fatty conversion, 4 in which expression of lipogenic markers is still efficiently repressed, as in normal myocardium.
In conclusion, compared analysis of RV and LV in a series of ARVC patients clearly suggested a decreased expression of PPARa and mitochondrial b-oxidation, indicating alterations in energy production in both heart ventricles. Functional studies of myosin revealed alterations in the RV, and to a lower extent in the LV, whereas PPARg overexpression was restricted to the RV. Accordingly, disruption of lipid homeostasis in the RV might be involved in the development of functional alterations. Altogether, our data appear consistent with a model of fat accumulation involving imbalance between fatty acid oxidation and fatty acid uptake. Finally, pathogenic alterations often displayed ventriclespecific patterns, pointing to the complexity of disease mechanisms in different heart areas, which will still require a lot of effort to be unravelled.
